Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare.The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, has selected 15 high-cost prescription drugs for government price negotiations. This is the first time the list includes drugs administered in doctors’ offices, not just medications that patients pick up at a pharmacy.Negotiations with participating drug companies will take place in 2026, and any negotiated or renegotiated prices will go into effect in January 2028. Drug companies...

6 days ago

On HALO